Liver stiffness measurements and FIB-4 are predictors of response to sofosbuvir-based treatment regimens in 7256 chronic HCV patients-Reference-Cited by-同舟云学术

Liver stiffness measurements and FIB-4 are predictors of response to sofosbuvir-based treatment regimens in 7256 chronic HCV patients

Published:2019-08-16 Issue:10 Volume:13 Page:1009-1016
ISSN:1747-4124
Container-title:Expert Review of Gastroenterology & Hepatology
language:en
Short-container-title:Expert Review of Gastroenterology & Hepatology

Author:

Abdel Alem Shereen¹^ORCID,Elsharkawy Aisha¹,El Akel Wafaa¹,Abdelaziz Ashraf O¹,Salama Rabab Maamoun¹,El-Sayed Manal Hamdy²,El Kassas Mohamed³,Anees Mahmoud⁴,Shedeed Mahmoud⁵,Abdelsalam Fatma⁶,Ziada Dina H⁴,El Shazly Yehia⁷,El-Serafy Magdy¹,Waked Imam⁸,Esmat Gamal¹,Doss Wahid¹

Affiliation:

1. Endemic Medicine and Hepatogastroenterology Department, Faculty of Medicine, Cairo University, Cairo, Egypt

2. Pediatrics department, Faculty of Medicine, Ain Shams University, Cairo, Egypt

3. Endemic Medicine Department, Faculty of Medicine, Helwan university, Cairo, Egypt

4. Department of Tropical Medicine & Infectious Diseases, Faculty of Medicine, Tanta University, Tanta, Egypt

5. Department of infectious and Endemic Diseases, Faculty of medicine, Suez Canal University, Ismailia, Egypt

6. Department of hepatology, gastroenterology and infectious diseases, Banha University, Banh, Egypt

7. Internal Medicine Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt

8. Department of Hepatology, National Liver Institute, Menoufyia University, Menoufyia, Egypt

Publisher

Informa UK Limited

Subject

Gastroenterology,Hepatology

Link

https://www.tandfonline.com/doi/pdf/10.1080/17474124.2019.1653183

Reference35 articles.

1. Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence

2. Benefit–risk assessment of new and emerging treatments for hepatitis C: focus on simeprevir and sofosbuvir

3. Impact of high-dose peginterferon alfa-2A on virological response rates in patients with hepatitis C genotype 1: A randomized controlled trial

4. Low virological response and high relapse rates in hepatitis C genotype 1 patients with advanced fibrosis despite adequate therapeutic dosing

5. Liver Biopsy

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Metabolic, renal, and hematological changes in chronic hepatitis C patients achieving rapid virologic response after 12 weeks of direct-acting antiviral treatment: A prospective cohort study;PLOS ONE;2023-09-01

2. Establishing a research production line in real-life settings: the case of Hepatitis C management in a viral hepatitis specialized Egyptian center;Current Medical Research and Opinion;2022-02-15

3. The role of fibrosis index FIB-4 in predicting liver fibrosis stage and clinical prognosis: A diagnostic or screening tool?;Journal of the Formosan Medical Association;2022-02

4. Elastography as a predictor of liver cirrhosis complications after hepatitis C virus eradication in the era of direct-acting antivirals;World Journal of Hepatology;2021-11-27

5. Development of a gene signature for predicting cirrhosis risk score of chronic liver disease associated with HCV infection in Egyptians;Microbial Pathogenesis;2021-04